SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001562180-23-002911
Filing Date
2023-03-17
Accepted
2023-03-17 16:10:56
Documents
2
Period of Report
2023-03-15

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 3  
1 PRIMARY DOCUMENT primarydocument.xml 3 10280
2 POWER OF ATTORNEY jumsteadpoa.txt EX-24 3391
  Complete submission text file 0001562180-23-002911.txt   15228
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Issuer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O G1 THERAPEUTICS, INC. 700 PARK OFFICES DRIVE, SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address
Umstead John V. (Reporting) CIK: 0001967910 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38096 | Film No.: 23742656